The legal status of TB-500 sits in a regulatory gray area that confuses many researchers and institutions. This synthetic version of Thymosin Beta-4, a naturally occurring peptide in nearly all human cells, is neither scheduled as a controlled substance nor approved for human investigational use by the FDA. Understanding where TB-500 stands legally requires examining …

GLP-1 receptor agonists have transformed metabolic research over the past decade, offering unprecedented insights into glucose regulation, satiety mechanisms, and body weight control. These peptides mimic the action of glucagon-like peptide-1, an incretin hormone that plays a central role in postprandial glucose metabolism. While research continues to expand our understanding of these compounds, it’s equally …

Understanding the FDA’s Position on BPC-157 The regulatory status of BPC-157 changed dramatically in February 2024 when the FDA issued guidance explicitly prohibiting compounded drugs containing this peptide. While the term “blacklisted” isn’t official FDA terminology, the agency’s position is clear: BPC-157 cannot legally be prescribed, compounded, or marketed for human use in the United …

GLP-1 receptor agonists like GLP1-S have gained attention in metabolic research, but their potential to interact with oral medications raises important questions for laboratory studies. Understanding these interactions is critical for researchers designing comprehensive protocols that account for pharmacokinetic and pharmacodynamic variables. The gastroparetic effects of GLP-1 receptor agonists can significantly alter the absorption profile …